C
CGN
vs
S
S&P TSX Composite Index (Canada)
Over the past 12 months, CGN has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +35% growth.
Stocks Performance
CGN vs S&P TSX Composite Index (Canada)
Performance Gap
CGN vs S&P TSX Composite Index (Canada)
Performance By Year
CGN vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cognetivity Neurosciences Ltd
Glance View
Cognetivity Neurosciences Ltd. operates as a technology company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-03-19. The firm is engaged in developing a cognitive testing platform, the integrated cognitive assessment (ICA), for use in medical and commercial environments for allowing early diagnosis of dementia. The Company’s ICA uses artificial intelligence and machine learning techniques to detect the earliest signs of cognitive impairment by testing the performance of brain. Its products include CognICA and OptiMind. The CognICA has various applications from early detection of cognitive impairment in dementia and multiple sclerosis (MS), to long-term health monitoring, corporate wellness, and personalized brain health. The OptiMind is a wellness app that measures individuals everyday cognitive performance. The firm serves various industries, including healthcare, elder care, enterprise, everyday use, and research. The ICA is available for clinical use in the United States of America, United Kingdom and Europe.
